ArticleDrug design, development and therapy2026
Efficacy and Safety of Different Colistin Administration Routes for Nosocomial Pneumonia Caused by Carbapenem-Resistant Organisms: A Single Centre, Open Label, Prospective Cohort Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Safety of Different Colistin Administration Routes for Nosocomial Pneumonia Caused by Carbapenem-Resistant Organisms: A Single Centre, Open Label, Prospective Cohort Study [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of inhaled colistin as either an adjunctive or substitution for nosocomial pneumonia (NP) caused by carbapenem-resistant organisms (CRO) is highly debated due to conflicting clinical evidence. Given the limitations of intravenous therapy, the optimal administration strategy remains a critical, unresolved question. This study aimed to compare the efficacy and safety of three colistin-based regimens administered via different routes. Methods: In this prospective cohort study, 127 intensive care unit (ICU) patients diagnosed with CRO-related NP and treated with colistin were enrolled. Patients were classified into three groups according to the route of administration: inhalation (IH group), intravenous colistin with adjunctive inhalation (IV+IH group), and intravenous (IV group) therapy. The primary endpoint was clinical efficacy at the end of treatment. Key secondary outcomes included microbiological eradication and nephrotoxicity. Results: Clinical efficacy was achieved in 72.1% of the IH group, 67.4% of the IV+IH group, and 65% of the IV group, with no statistically significant difference among groups ( Conclusion: In critically ill patients with CRO-associated NP, inhaled colistin monotherapy provided comparable clinical efficacy to systemic administration. It achieved superior microbiological eradication and showed a favorable safety profile regarding nephrotoxicity, suggesting it represents a viable and potentially safer therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.